Plain-English translation of NCT05524090 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →This is an implementation program—not a drug trial—designed to bring advanced surgical techniques for locally advanced pancreatic cancer to hospitals across the Netherlands. Patients who have received at least 4 months of chemotherapy (either mFOLFIRINOX or gemcitabine-nab-paclitaxel) and whose cancer is not getting worse will be carefully evaluated by an expert panel to see if they are candidates for surgery. The goal is to give more patients the chance at longer survival through surgery, following methods already proven successful at leading international cancer centers.
Right now, only about 8% of Dutch pancreatic cancer patients with locally advanced disease receive surgery after chemotherapy, compared to 25% at top international hospitals. This trial exists to close that gap and ensure that Dutch patients have fair access to surgical options that can improve survival.
You likely qualify if…
You likely don't qualify if…
If you qualify, your medical records and scans will be reviewed by an international expert panel to determine whether surgery is a safe option for you. If the panel recommends surgery, you would travel to one of three specialized Dutch hospitals to have the procedure performed by experienced surgeons trained in these advanced techniques. The program runs through 2030 and involves close coordination between your local hospital and the surgical center, with follow-up care to monitor your recovery and long-term outcomes.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Netherlands